SUMMARY OF BASIC AND CLINICAL STUDIES ON PIVMECILLINAM CONDUCTED IN JAPAN
1977 Volume 25 Issue 1 Pages 1-11
Details
1977 Volume 25 Issue 1 Pages 1-11
1. Mecillinam, which is the active form of pivmecillinam, showed remarkably potent antibacterial activity against E. coli. Proteus, Klebsiella and Enterobacter were also susceptible to the drug.
2. Antibacterial activity and bactericidal action of mecillinam were influenced by inoculum sizes.
3. Morphological study revealed that E. coli did not make filament-shaped cells but swollen round-shaped cells in the presence of mecillinam.
4. In vitro synergistic effects of mecillinam with other penicillins and cephalosporins were demonstrated.
5. Pivmecillinam was clinically effective in patients infected by ampicillinor amoxicillin-resistant E. coli.
6. Main indications of pivmecillinam may be urinary-tract infections. The drug was satisfactorily effective at daily doses of 150-200 mg for simple urinary-tract infections, but it was sometimes necessary to increase doses up to 300-400 mg per day for complicated urinary-tract infections. Thus, the drug has its merit in good efficacy with lower doses than conventional oral penicillins.
7. The drug was well tolerated in clinical use, and caused comparatively few adverse reactions though GOT and GPT elevation and RBC decrease were reported.
